Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2017

John Sninsky's Biography



John Sninsky, Chief Scientific Officer, CareDx

John Sninsky, Ph.D. is Chief Scientific Officer at CareDx, Inc., a California based molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. John brings experience in the discovery, development and application of diagnostic technologies, content and interpretive test solutions ranging from early stage biotechnology to international pharmaceutical organizations as well as in a range of small and enterprise diagnostic services and product settings.

John Sninsky Image

Donor-Derived Cell-Free DNA: An Accurate, Precise, and Dynamic Biomarker for Improved Management of Solid Organ Transplant Patients

Tuesday, 21 March 2017 at 09:00

Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com

Cell-free DNA (cfDNA) has been described as a biomarker for prenatal testing, cancer, and organ transplantation, each of which present different clinical and technological challenges. cfDNA circulating in the plasma of transplant recipients represents a mixture of recipient cfDNA and residual nucleosome-protected genomic regions released from dying cells of the allograft (“transgenome”). The genomes of the organ donor and allograft recipient are distinguishable by sequencing total cfDNA from the plasma. A clinical-grade cfDNA NextGen sequencing (NGS) assay was developed to monitor the levels of the “transgenome”, enabling assessment of the allograft status of transplant recipients with high confidence analytical validation. The NGS-based assay does not require testing of genetic material from the donor or recipient thereby simplifying the testing of transplants with cadaveric donors.  Longitudinal samples from heart, lung and kidney transplant patients had higher dd-cfDNA levels at biopsy-confirmed rejection which were reduced following adjustments to immunosuppressive therapy in clinical validation studies. Serial assessment of dd cfDNA provides a measure of both the amount and kinetics of dying allograft cells, information clinicians may use to inform clinical utility.


Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonCirculating Biomarkers World Congress 2017Circulating Biomarkers World Congress 2017 in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com